Advanced Enzyme Technologies Ltd (ADVENZYMES) AI Stock Analysis

• Market Cap: ₹33.86B
• Dividend Yield: 1.7%
• Average Volume (3M): 13.78K
• Price to Earnings (P/E): 23.0
• Beta (1Y): 1.10
• Revenue Growth: 14.11%
• EPS Growth: 7.47%
• Country: IN
• Employees: 323
• Sector: Healthcare
• Sector Strength: 45
• Industry: Chemicals - Specialty
• EPS (TTM): 3.90
• Shares Outstanding: 111,926,800
• 10 Day Avg. Volume: 10,375
• 30 Day Avg. Volume: 13,779
• PEG Ratio: -13.34
• Price to Book (P/B): 2.27
• Price to Sales (P/S): 5.07
• P/FCF Ratio: 28.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 65 Neutral
• Price Target: ₹348.00 ▲(14.76% Upside)

Advanced Enzyme Technologies Ltd scores well in financial performance due to its strong revenue and profit growth, solid margins, and effective leverage management. However, technical analysis indicates bearish momentum and valuation metrics suggest the stock is fairly priced but not a standout in terms of value. The absence of earnings call data and corporate events limits further insights.

Positive Factors

Revenue Growth

Consistent revenue growth indicates a strong market position and effective product demand, supporting long-term business sustainability and expansion.

Profit Margins

High profit margins reflect strong pricing power and operational efficiency, enhancing the company's ability to invest in growth and withstand market fluctuations.

Leverage Management

Strong leverage management with low debt levels reduces financial risk and enhances the company's capacity to invest in strategic opportunities.

Negative Factors

EBIT Margin Decline

A decline in EBIT margin indicates potential inefficiencies that could affect profitability if not addressed, requiring management focus on cost control.

Modest Free Cash Flow Growth

Modest free cash flow growth limits the company's ability to fund new projects and return capital to shareholders, potentially impacting long-term growth.

EPS Growth Decline

A decline in EPS growth suggests challenges in profitability expansion, which could impact investor confidence and future capital raising capabilities.

Advanced Enzyme Technologies Ltd Business Overview & Revenue Model

Company Description

Advanced Enzyme Technologies Limited researches and develops, manufactures, and markets enzymes and probiotics in India, the United States, Asia, Europe, and internationally. The company offers enzymes for human healthcare and animal nutrition, fruit and vegetable processing, baking, brewing, and malting, and grain processing, protein modification, yeast processing, dairy and cheese processing, and oils and fats processing, as well as for specialty applications. It also provides non-food processing enzymes for textile processing, leather, pulp and paper, detergents and cleaning aids, bio-fuels, and biocatalysis. The company was formerly known as Advanced Biochemicals Limited and changed its name to Advanced Enzyme Technologies Limited in 2005. Advanced Enzyme Technologies Limited was founded in 1957 and is based in Thane, India.

How the Company Makes Money

ADVENZYMES generates revenue primarily through the sale of its enzyme products across multiple sectors. The company's revenue model is built on both direct sales to customers and collaborations with industry partners. Key revenue streams include the sale of specialized enzymes for food processing, which improve texture and flavor, as well as enzymes for the animal feed industry that enhance nutritional absorption. Additionally, ADVENZYMES earns revenue from licensing agreements and research collaborations with other companies and institutions, which enable the development of tailored enzyme solutions. Strategic partnerships with major players in various industries further bolster its revenue, as they expand market reach and create opportunities for joint product development.

Advanced Enzyme Technologies Ltd Financial Statement Overview

Summary

Advanced Enzyme Technologies Ltd demonstrates a strong financial position with consistent revenue and profit growth, solid profit margins, and effective leverage management. While the slight decline in EBIT margin and modest free cash flow growth present areas for improvement, the company remains financially sound with minimal risk.

Income Statement

Advanced Enzyme Technologies Ltd shows a strong income statement with consistent revenue growth, evidenced by a 6.8% increase in the latest year. The company maintains high profit margins, with a net profit margin of over 20% and a gross profit margin around 48%. However, the slight decline in EBIT margin suggests efficiency improvements are needed. Overall, the company is financially healthy with robust profitability.

Balance Sheet

The balance sheet indicates a solid financial structure with a low debt-to-equity ratio of 0.03, showcasing strong leverage management. The equity ratio stands at a stable 87.6%, indicating reliance on equity financing. The return on equity is healthy at 9.2%, though slightly lower than industry leaders. Overall, the company displays a stable and conservative balance sheet with minimal financial risk.

Cash Flow

The cash flow statement reflects robust operating cash flows with a steady growth trend. The free cash flow to net income ratio is favorable, indicating efficient cash generation relative to earnings. However, the free cash flow growth rate has been modest. The company manages its capital expenditures prudently, but could enhance free cash flow growth further.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	6.68B	6.37B	6.23B	5.41B	5.29B	5.00B
Gross Profit	4.54B	3.07B	4.64B	3.98B	4.09B	3.95B
EBITDA	2.35B	2.27B	2.27B	1.79B	2.09B	2.41B
Net Income	1.37B	1.31B	1.33B	1.06B	1.20B	1.46B
Balance Sheet
Total Assets	0.00	16.21B	15.35B	14.22B	12.68B	11.53B
Cash, Cash Equivalents and Short-Term Investments	5.92B	5.88B	5.48B	4.86B	3.74B	3.17B
Total Debt	0.00	393.50M	473.08M	334.99M	347.30M	279.63M
Total Liabilities	-14.69B	1.53B	1.64B	1.38B	1.27B	1.22B
Stockholders Equity	14.69B	14.21B	13.24B	12.35B	10.89B	9.71B
Cash Flow
Free Cash Flow	0.00	1.15B	990.56M	1.02B	941.15M	1.43B
Operating Cash Flow	0.00	1.49B	1.41B	1.40B	1.22B	1.63B
Investing Cash Flow	0.00	-990.44M	-646.49M	-2.98B	-249.12M	-260.33M
Financing Cash Flow	0.00	-692.02M	-592.38M	-257.98M	-273.75M	-263.10M

Advanced Enzyme Technologies Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 303.25
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ADVENZYMES, the sentiment is Negative. The current price of 303.25 is below the 20-day moving average (MA) of 304.22, below the 50-day MA of 311.17, and below the 200-day MA of 311.92, indicating a bearish trend. The MACD of -1.77 indicates Negative momentum. The RSI at 46.78 is Neutral, neither overbought nor oversold. The STOCH value of 68.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ADVENZYMES.

Advanced Enzyme Technologies Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RPGLIFE	76 Outperform	₹38.62B	17.93	―	0.85%	―	―
ADVENZYMES	65 Neutral	₹33.86B	22.96	―	1.70%	14.11%	7.47%
DCAL	63 Neutral	₹40.37B	29.87	―	―	5.38%	―
SEQUENT	58 Neutral	₹50.35B	115.28	―	―	14.39%	152.14%
GUFICBIO	57 Neutral	₹32.08B	56.36	―	0.03%	7.78%	-34.68%
MOREPENLAB	57 Neutral	₹21.46B	21.76	―	0.49%	-0.29%	-29.04%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Advanced Enzyme Technologies Ltd Corporate Events

Advanced Enzyme Technologies Announces Special Window for Share Transfer Requests

Advanced Enzyme Technologies Ltd has announced a special window for the re-lodgement of transfer requests for physical shares, as per Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This initiative, published in the Free Press Journal and Navshakti, aims to inform shareholders holding physical shares about the opportunity to re-submit their transfer requests, potentially impacting the company’s shareholder engagement and compliance processes.